In the Zone: biomarkers and Alzheimer’s disease

Alzheimer’s disease is a devastating neurodegenerative disease and the only one of the top 10 deadly diseases that have almost no treatment. FDA approved ADUHELM® from Biogen (MA, USA) in 2021, which was the first approved Alzheimer’s treatment in the past 2 decades. The current treatment plan focuses on preventing the formation and aggregation of plaque proteins called amyloids and taus, or removing such proteins. ADUHELM® adopted the latter pathway. However, from a diagnostic point-of-view, we have moved slightly ahead of time compared to the treatment, thanks to various new current technologies. High sensitivity technologies and platforms help enable early diagnostics. With this, the diagnosis of Alzheimer’s disease enters the era of biomarkers. These two biomarkers, amyloids and taus, define Alzheimer’s disease.

INFOGRAPHIC

INZ CAR-TBiomarker and Alzheimer’s disease: role of high sensitivity assays and the applications – This infographic focuses on how new developments in technology have advanced Alzheimer’s disease diagnosis. Importantly, high sensitivity technologies and platforms have enabled early diagnostics. With this, the diagnosis of Alzheimer’s disease enters the era of biomarkers.

 

 

WEBINAR

Bioanalysis Zone hexagon

Biomarker and Alzheimer disease: role of high sensitivity assays and the applications – Alzheimer’s disease is a devastating neurodegenerative disease, which is the only one amongst the top 10 deadly diseases that has almost no treatment. However, from the diagnostic point-of-view, we are slightly ahead of time compared with the treatment, thanks to various new technologies. In particular, highly sensitive technology and platforms enable early diagnostics. This presentation will focus on highly sensitive protein biomarker assays developed and validated at a testing laboratory and its application for the diagnosis of Alzheimer’s disease.

 

[Video edit by Andrew McKinnon]

In association with: